Blood-brain barrier (BBB) dysfunction has been shown to play a causal role in both early- and late-onset Alzheimer's disease (EOAD, LOAD). While much has been learned about the molecular mechanisms of BBB function and dysfunction in AD from mouse model systems, many important unanswered questions remain regarding how AD-associated mutations and genetic variants affect human BBB integrity and function. Improved human experimental systems are required to complement existing animal models. Pioneering studies by co-PI Ingber have produced microfluidic 3D organ-on-chip models, including a BBB-on-a-chip (BBB- Chip), increasingly representative of human in vivo physiology. We have adapted this system to create isogenic iPSC-derived BBB-Chip models of normal human subjects and of subjects with EOAD and LOAD. The Young-Pearse lab has generated a collection of iPSC lines that capture the diverse set of genetic risk factors for AD including: EOAD mutation of APP and corrected controls, DS and DS with removal of copies of high impact chr21 genes, an isogenic APOE series including APOE 2/2, 3/3, 4/4 and KO, and a collection of lines that we've generated from over 50 individuals in the ROS/MAP cohorts that represent the clinical and pathological spectrum of LOAD. Here, we propose to combine the BBB-Chip model with the iPSC line collection to examine the impact of early- and late-onset genetic variants on BBB function, and to define the molecular pathways impacted by these variants. In the first aim, we address the hypothesis that neurons expressing EOAD mutations secrete A? species that negatively affect BBB integrity through toxic effects on brain microvasculature endothelial cells (BMVECs). We will use human BBB in vitro models to examine A?- dependent and independent impacts of trisomy 21 and fAD mutation on BBB integrity and function via a) measurements of transendothelial electrical resistance (TEER), b) permeability assays, and c) immunocytochemistry and morphological analyses of BBB cells. In addition, we will identify the molecular pathways affected in EOAD in BMVECs, pericytes and astrocytes via RNA sequencing and unbiased proteomics.
In aim 2, we determine the functional impact of altered composition of A? aggregates on clearance of pathologic A? across the BBB. To this end, we will use a variety of well defined synthetic A? species as well as human neuron-derived and brain-derived A? to systematically define how A? composition and aggregation state affects: 1) uptake and transcytosis of A? across the BBB and 2) integrity of the BBB and health of the pericytes, astrocytes and BMVECs composing the BBB. Finally, in the third aim we address the hypothesis that the LOAD risk genes SORL1 and CLU work in concert with APOE to mediate A? clearance by the BBB. In this aim, we will determine the functional consequences of variants of APOE, CLU and SORL1 on BBB integrity and A? clearance. Finally, we will determine the molecular consequences of modulation of APOE, CLU and SORL1 in BMVECs, pericytes and astrocytes in our human BBB experimental system.
The blood-brain barrier (BBB) tightly regulates the ?ow of factors from the blood into the brain. Breakdown of the BBB has been associated with cognitive decline and Alzheimer's disease, but the molecular mechanisms linking BBB dysfunction with Alzheimer's disease are not fully understood. Genetic studies of Alzheimer's disease have implicated a set of genes that are active in cells of the BBB. Here, we will use an entirely human experimental system to determine the function and mechanisms of action of these genes.
